NewsBenzingaMIRA Pharma Reports 21-Day Preclinical Proof-Of-Concept Study Showing That Once-Daily Oral MIRA-55 Significantly Reduced Mechanical And Thermal Pain Hypersensitivity; Results Back MIRA-55's Progress Toward IND Filing MIRA Pharma Reports 21-Day Preclinical Proof-Of-Concept Study Showing That Once-Daily Oral MIRA-55 Significantly Reduced Mechanical And Thermal Pain Hypersensitivity; Results Back MIRA-55's Progress Toward IND Filing Benzinga 2026.10.22 12:07 (GMT+0) Open on Benzinga Other news "White-Haired Stock Guru" Serenity Slams SIVE Management: Lack of Clear Commitment to Nasdaq Listing Timeline Heightens Market Concerns Apple, Peter Thiel and the iPhone Duo Set Up a High-Stakes Weekend for Investors: This Week in Appleverse Wall Street Week Ahead Peabody: The Global Energy Market Landscape Is Changing In Coal's Favor (NYSE:BTU) Ermenegildo Zegna: Stronger DTC Sales And Operating Leverage Support Further Upside Apollo Chief Economist: AI Has Yet to Deliver Returns for US Companies Outside Tech
"White-Haired Stock Guru" Serenity Slams SIVE Management: Lack of Clear Commitment to Nasdaq Listing Timeline Heightens Market Concerns
Apple, Peter Thiel and the iPhone Duo Set Up a High-Stakes Weekend for Investors: This Week in Appleverse
